Suchergebnisse

Pembina Pipeline Corporation PBA has laid out an ambitious yet disciplined roadmap, targeting 5%-7% compound annual growth in fee-based adjusted EBITDA per share through 2030. The outlook reflects a

Target (TGT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of

Target (TGT) ended the recent trading session at $119.84, demonstrating a +2.43% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 1.67% for

Target (TGT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near

In the latest close session, Target (TGT) was up +1.46% at $122.21. The stock exceeded the S&P 500, which registered a gain of 0.44% for the day. Meanwhile, the Dow gained 0.36%, and the Nasdaq, a

IREN Limited IREN is increasing its AI cloud capacity to 150,000 graphics processing units (GPUs), which management believes is the key to support its target of more than $3.7 billion in AI cloud

If you've been stuck searching for Allocation Balanced funds, consider Vanguard Target Retirement Income Fund (VTINX) as a possibility. While this fund is not tracked by the Zacks Mutual Fund Rank

Autodesk (ADSK) closed the last trading session at $247.99, gaining 9.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

Shares of Intuit (INTU) have gained 19.7% over the past four weeks to close the last trading session at $455.56, but there could still be a solid upside left in the stock if short-term price targets

Intellicheck Mobilisa, Inc. (IDN) closed the last trading session at $5.54, gaining 13.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets

Lumen Technologies, Inc. LUMN is advancing a structured cost transformation plan aimed at achieving $1 billion in run-rate cost reductions by the end of 2027. On the last earnings call, management

GSK plc GSK announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug

The intensifying war in the Middle East over the past month has emerged as a central narrative shaping global commodity markets. The conflict, which has evolved from localized skirmishes to targeted

As of the 2025 fourth-quarter end, Auna S.A.’s AUNA net leverage held steady at 3.6X Net Debt-to-Adjusted EBITDA. The company is aiming to reduce its leverage below 3X over the medium term

Weatherford International plc WFRD is positioning itself for a second-half rebound supported by international activity and disciplined execution. The setup combines improving margins with steady

Shares of Block (XYZ) have gained 20.5% over the past four weeks to close the last trading session at $61.17, but there could still be a solid upside left in the stock if short-term price targets of